RBC Capital Keeps Kymera at Sector Perform, Raises Target to $116

RBC Capital raised its price target for Kymera Therapeutics to $116 from $112 while maintaining its Sector Perform rating. The target implies 5.4% downside from the Oct. 29 close of $122.60.